Mesoblast Net Income from 2010 to 2026
| MESO Stock | USD 16.92 1.38 7.54% |
Net Loss | First Reported 2012-09-30 | Previous Quarter -27.1 M | Current Value -27.1 M | Quarterly Volatility 12.9 M |
Check Mesoblast financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mesoblast's main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.7 M, Interest Expense of 27.7 M or Selling General Administrative of 20.8 M, as well as many indicators such as Price To Sales Ratio of 79.18, Dividend Yield of 0.0 or PTB Ratio of 2.28. Mesoblast financial statements analysis is a perfect complement when working with Mesoblast Valuation or Volatility modules.
Mesoblast | Net Income | Build AI portfolio with Mesoblast Stock |
Evaluating Mesoblast's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Mesoblast's fundamental strength.
Latest Mesoblast's Net Income Growth Pattern
Below is the plot of the Net Income of Mesoblast over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Mesoblast financial statement analysis. It represents the amount of money remaining after all of Mesoblast operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Mesoblast's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mesoblast's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (102.14 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Mesoblast Net Income Regression Statistics
| Arithmetic Mean | (74,116,464) | |
| Coefficient Of Variation | (43.52) | |
| Mean Deviation | 23,163,134 | |
| Median | (81,889,000) | |
| Standard Deviation | 32,254,562 | |
| Sample Variance | 1040.4T | |
| Range | 117.9M | |
| R-Value | (0.50) | |
| Mean Square Error | 829.9T | |
| R-Squared | 0.25 | |
| Significance | 0.04 | |
| Slope | (3,207,391) | |
| Total Sum of Squares | 16645.7T |
Mesoblast Net Income History
Other Fundumenentals of Mesoblast
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Mesoblast Net Income component correlations
About Mesoblast Financial Statements
Mesoblast investors utilize fundamental indicators, such as Net Income, to predict how Mesoblast Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -91.9 M | -87.3 M | |
| Net Loss | -91.9 M | -96.5 M | |
| Net Loss | -73.7 M | -77.4 M | |
| Net Loss | (0.10) | (0.11) | |
| Net Income Per E B T | 0.90 | 0.73 |
Pair Trading with Mesoblast
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mesoblast position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mesoblast will appreciate offsetting losses from the drop in the long position's value.Moving together with Mesoblast Stock
Moving against Mesoblast Stock
| 0.67 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.55 | EVGN | Evogene | PairCorr |
| 0.46 | GNLX | Genelux Common | PairCorr |
| 0.41 | JUMP | Leveljump Healthcare Corp | PairCorr |
| 0.37 | EDIT | Editas Medicine Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Mesoblast could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mesoblast when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mesoblast - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mesoblast to buy it.
The correlation of Mesoblast is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mesoblast moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mesoblast moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mesoblast can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Mesoblast Correlation against competitors. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Will Biotechnology sector continue expanding? Could Mesoblast diversify its offerings? Factors like these will boost the valuation of Mesoblast. Expected growth trajectory for Mesoblast significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mesoblast data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.85) | Revenue Per Share | Quarterly Revenue Growth 4.586 | Return On Assets | Return On Equity |
Investors evaluate Mesoblast using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Mesoblast's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Mesoblast's market price to deviate significantly from intrinsic value.
Understanding that Mesoblast's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mesoblast represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Mesoblast's market price signifies the transaction level at which participants voluntarily complete trades.